Latest News
Read the latest corporate announcements, scientific developments and company news from Glycotest.
Glycotest’s Patent Portfolio Covering Important Asian Liver Disease Diagnostic Market Grows through Grant of Hong Kong Patent.
Glycotest’s Patent Portfolio Covering Important Asian Liver Disease Diagnostic Market Grows through Grant of Hong Kong Patent.
Read more →Glycotest Announces Start of Enrollment in Its Case-Control Study of the HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma (NCT03878550).
Glycotest Announces Start of Enrollment in Its Case-Control Study of the HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma (NCT03878550).
Read more →Glycotest, Inc. Receives $3 Million First Tranche of $10 Million Series A Financing
New York, NY—February 14, 2019 Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today that the Company has received the first $3 million…
Read more →Glycotest Receives Additional US Patent Protection for Its Test for Liver Fibrosis-Cirrhosis.
Glycotest Receives Additional US Patent Protection for Its Test for Liver Fibrosis-Cirrhosis.
Read more →Glycotest’s Coverage of Key Biomarker Fucosylated Kininogen Extended by Canadian Patent
Glycotest’s Coverage of Key Biomarker Fucosylated Kininogen Extended by Canadian Patent
Read more →Glycotest™ Closes $10 Million Series A Financing with Fosun Pharma
New York, NY—October 22, 2018. Glycotest Inc., Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today the close of a Series A funding round…
Read more →Glycotest Announces Grant of US Patent Extending Coverage of Its Fucosylated Biomarker Diagnostic Technology for Serious Liver Disease
Glycotest Announces Grant of US Patent Extending Coverage of Its Fucosylated Biomarker Diagnostic Technology for Serious Liver Disease
Read more →Glycotest™ HCC Panel Completes Successful Clinical Product Evaluation
New York, NY – 04 January 2018 – Glycotest Inc., announced today that it successfully completed a clinical evaluation of its HCC Panel in China. In a blinded evaluation of 149 HCC patient and…
Read more →Glycotest™ Expands Patent Portfolio with Chinese Patent
Glycotest™ Expands Patent Portfolio with Chinese Patent
Read more →